Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine Rentosertib represents a novel mechanism, novel AI-identified target, and novel AI-empowered molecule emerging from Insilico's aging-biology-driven Pharma.AI platform The GENESIS-IPF Phase IIa study showed manageable safety...
NYSE Content Update: Teradata AI Report Surveys 1,000 Global Tech + Data Leaders
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 7, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Annovis reveals latest feat...
Piramal Pharma’s FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
MUMBAI, India, July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal...
Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma
EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, has received the American Chemical Society's 2026 Green Chemistry Challenge Award for the Greener Synthetic Pathway in the Synthesis of Pharmaceuticals. The...
HKSH’s First-in-Asia Comparative Study on Radiotherapy for Breast Cancer Reveals Hypofractionated Proton Therapy Prevents Breast Cancer Recurrence with 100% Survival Rate
Minimises Cardiopulmonary Concerns and Maintains Quality of Life HONG KONG, July 7, 2026 /PRNewswire/ -- The HKSH Cancer Centre under HKSH Medical Group (HKSH) introduced proton therapy in 2023, covering a wide range of cancer types including breast, prostate as well as head and neck cancers, and has since accumulated about 940 cases of clinical data. Around 45% of...
Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases
BIRMINGHAM, England, July 7, 2026 /PRNewswire/ -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million oversubscribed seed financing round led by Empirical Ventures, with participation from DEBRA Research, Cure EB, Oshen Bio and existing investor SFC Capital. Proceeds will support pre-clinical development, manufacturing...
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001),...
Bayer Foundation Women Entrepreneurs Award: From AI Diagnostics to Circular Food Tech, 15 Women Are Transforming Health and Food Systems Worldwide
LEVERKUSEN, Germany and VIENNA, July 7, 2026 /PRNewswire/ -- The Bayer Foundation Women Entrepreneurs Award, powered by the Impact Hub Network, honours 15 women from Latin America, Africa, and Asia addressing critical challenges in global healthcare and food security. Selected from 1,172 applicants across 124 countries, this year's winners are advancing innovations from digital...
BIOHK2026 (Hong Kong International Biotechnology Conference and Exhibition), 9-12 September, Hong Kong – Connecting Global Leaders in Biotechnology
Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September. HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026), jointly organized by the Hong Kong Biotechnology Organization and Reed Sinopharm Exhibitions, will take place from September 9 to...
Aureka Releases OpenDDE, an Open-Source Drug Discovery Engine Designed to Accelerate AI-Driven Therapeutic Discovery
All-atom biomolecular foundation model uses co-folding as the entry point to a scalable drug discovery engine; the release marks a concrete step toward advancing open scientific AI for future biomedical research that benefit patients. LAGUNA HILLS, Calif. and SHANGHAI, July 7, 2026 /PRNewswire/ -- Aureka, an AI TechBio company building infrastructure for AI-driven biologics discovery, today announced the release...
